Terra Alpha Investments LLC Purchases New Shares in Agilent Technologies, Inc. (NYSE:A)

Terra Alpha Investments LLC purchased a new stake in Agilent Technologies, Inc. (NYSE:A) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 23,895 shares of the medical research company’s stock, valued at approximately $3,210,000. Agilent Technologies comprises about 3.2% of Terra Alpha Investments LLC’s holdings, making the stock its 13th biggest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Signaturefd LLC increased its position in shares of Agilent Technologies by 3.2% during the 4th quarter. Signaturefd LLC now owns 7,223 shares of the medical research company’s stock valued at $970,000 after purchasing an additional 226 shares during the last quarter. Cibc World Markets Corp increased its position in shares of Agilent Technologies by 14.5% during the 4th quarter. Cibc World Markets Corp now owns 45,340 shares of the medical research company’s stock valued at $6,091,000 after purchasing an additional 5,735 shares during the last quarter. Corient Private Wealth LLC increased its position in shares of Agilent Technologies by 0.6% during the 4th quarter. Corient Private Wealth LLC now owns 258,612 shares of the medical research company’s stock valued at $34,742,000 after purchasing an additional 1,665 shares during the last quarter. Frank Rimerman Advisors LLC increased its position in shares of Agilent Technologies by 18.8% during the 4th quarter. Frank Rimerman Advisors LLC now owns 1,630 shares of the medical research company’s stock valued at $219,000 after purchasing an additional 258 shares during the last quarter. Finally, Catalyst Funds Management Pty Ltd increased its position in shares of Agilent Technologies by 116.7% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 2,600 shares of the medical research company’s stock valued at $349,000 after purchasing an additional 1,400 shares during the last quarter.

Analyst Ratings Changes

Several brokerages have recently issued reports on A. Citigroup raised their target price on Agilent Technologies to $165.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. cut their price target on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research note on Tuesday, November 26th. Sanford C. Bernstein cut their price target on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research note on Tuesday, November 26th. Wells Fargo & Company cut their price target on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. Finally, Barclays upgraded Agilent Technologies from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $135.00 to $145.00 in a research note on Monday, February 10th. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $146.15.

Agilent Technologies Stock Up 3.6 %

Shares of NYSE A opened at $121.53 on Monday. Agilent Technologies, Inc. has a 52 week low of $117.17 and a 52 week high of $155.35. The business has a 50-day simple moving average of $138.26 and a two-hundred day simple moving average of $137.96. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market cap of $34.65 billion, a P/E ratio of 27.94, a P/E/G ratio of 3.40 and a beta of 1.11.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Research analysts anticipate that Agilent Technologies, Inc. will post 5.57 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.82%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.76%.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.